Stefan Wohlfeil

Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland.

TRIN Pharma GmbH develops new small molecule drugs for an effective tumor treatment. Its research is focused on innovative compounds with a proprietary molecular structure, with high selectivity and potent anti-tumor activity. TRIN Pharma's business objective is the development of its molecules into clinical studies and commercialization.

Atani Ltd. manufactures and markets drugs. The firm's drugs are used for the treatment of cancer. The company was founded by Stefan Wohlfeil and is headquartered in Tokyo, Japan

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

OM Pharma SA engages in manufacture of pharmaceutical products. Its portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies, hemorrhoids, and menometrorrhagia. The company was founded by Jean-Rene Ricard in 1937 and is headquartered in Meyrin, Switzerland.

Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund.

Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education.

Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The private company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million.